NIH Invests $150 Million to Replace Animal Testing With Human-Based Research

The National Institutes of Health on March 18 announced the first awards under the Complement-ARIE program, committing over $150 million to develop human-based research methods that could fundamentally reshape how drugs are tested and approved in the United States.

The program — short for Complement Animal Research in Experimentation — funds seven technology development centers focused on new approach methodologies (NAMs), including organ-on-a-chip platforms and AI-driven physiological modeling. The FDA and EPA are formal partners, signaling that regulatory acceptance of these methods is advancing alongside the science.

Where the $150 Million Is Going

The initial awards target research areas where animal models have been least predictive of human outcomes: gynecological disorders, cardiac disease, neurological disorders, and rare diseases. Supporting infrastructure includes a NAMs Data Hub and Coordinating Center at New York University ($25 million over five years, in collaboration with Sage Bionetworks) to standardize data across all funded centers.

A separate $7 million NAMs Reduction to Practice Challenge, run jointly with the FDA and EPA, will test whether human-based methods can demonstrate viability within three years. A planned Validation and Qualification Network (approximately $20 million) will create a public-private partnership to bring proven NAMs to market.

Biotech and Pharma Researchers Should Pay Attention

The Complement-ARIE program is not merely academic. The FDA's parallel commitment to accept NAMs data in regulatory submissions means that companies developing organ-on-a-chip, computational biology, or in vitro testing platforms now have a funded pathway from bench to regulatory qualification.

Johns Hopkins, for example, received $15 million to develop a platform studying neurological diseases and screening chemicals — work with direct commercial applications.

How to Position for Future Funding

While the initial center awards have been made, the Validation and Qualification Network is still pending, and additional NAMs challenges are expected. Small biotech firms and academic labs working on human-tissue models, AI-based toxicology, or microfluidics platforms should monitor the NIH Common Fund website for upcoming solicitations.

Researchers tracking federal life sciences funding through resources like grantedai.com will find that this program creates opportunities well beyond the initial awardees, particularly as the VQN scales.

For in-depth analysis of NIH funding trends, visit the Granted blog.